Table 3.
Estimate comparisons of one dose of ChAdOx1 in participants with prior SARS-CoV-2 infection >2 months post vaccination with two doses BNT162b2 in SARS-CoV-2 naïve participants >2 months post vaccination in the reference group. The estimate provides the multiplication factor for how much the AU/ml is modified by switching from two doses BNT162b2 in SARS-CoV-2 naïve participants to a single dose ChAdOx1 nCoV-19 in participants with prior SARS-CoV-2 infection. Estimates around 1.0 suggest no difference. All values are adjusted for sex and age. Inf; Infection, m; months, vx; vaccination, RBD; receptor binding protein, NAb; neutralizing antibodies. CI; confidence interval.
| RBD IgG |
RBD NAb |
|||||
|---|---|---|---|---|---|---|
| Estimate | 95% CI | Estimate | 95% CI | |||
| Wild type | ||||||
| Inf <11m prior vx | 1.4 | (1.0 to 2.1) | 1.2 | (1.0 to 1.3) | ||
| Inf >11m prior vx | 2.3 | (1.7 to 3.1) | 1.4 | (1.2 to 1.6) | ||
| Alpha (B.1.1.7) | ||||||
| Inf <11m prior vx | 1.5 | (1.0 to 2.2) | 1.5 | (1.2 to 1.9) | ||
| Inf >11m prior vx | 2.4 | (1.7 to 3.2) | 1.7 | (1.1 to 2.5) | ||
| Beta (B.1.351) | ||||||
| Inf <11m prior vx | 1.4 | (0.9 to 2.0) | 1.1 | (0.4 to 3.6) | ||
| Inf >11m prior vx | 2.4 | (1.7 to 3.2) | 3.6 | (1.3 to 9.4) | ||
| Gamma (P.1) | ||||||
| Inf <11m prior vx | 1.3 | (0.9 to 1.9) | 0.8 | (0.4 to 1.4) | ||
| Inf >11m prior vx | 2.2 | (1.6 to 3.0) | 1.2 | (0.8 to 1.9) | ||
| Delta (B.1.617.2) | ||||||
| Inf <11m prior vx | 1.2 | (0.9 to 1.8) | 1.1 | (1.0 to 1.2) | ||
| Inf >11m prior vx | 2.0 | (1.5 to 2.7) | 1.2 | (1.0 to 1.4) | ||